IPS Examines Reaction to Introduction of Fixed-Dose ARVs in South Africa
May 6, 2013
Noting "a serious supply shortage [of antiretroviral (ARV) treatment in South Africa last May], the most recent of several stockouts that have plagued the state-funded ARV treatment program since its launch in 2004," Inter Press Service examines reaction to the introduction of fixed-dose ARVs (FDAs) in the country last month. The news service notes, "Until now, state-funded ARV treatment has comprised three different pills taken at different times during the day. The new FDA combines the three key agents from these pills in a single pill that only needs to be taken once a day."
"Although welcoming the FDAs as easier and more convenient for patients, activists and health professionals alike have warned that a stockout of the drug could have a catastrophic effect on the country's public HIV/AIDS treatment program -- the largest of its kind in the world," IPS continues. "The risk of FDAs is that there isn't really a good fall-back," Kevin Rebe of the Anova Health Institute, "which runs the Health4Men program focusing on HIV prevention and treatment," tells IPS, the news service writes, adding, "He points out that even a few missed doses could result in resistance to treatment." However, the news service notes, "The introduction of FDAs is also expected to significantly reduce the state's annual bill for HIV/AIDS treatment" (Bendix, 5/6).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)